Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

21 oct. 2013 09h00 HE | Source: Mateon Therapeutics

OXiGENE Presents Preclinical Data Demonstrating Significant Antitumor Activity of ZYBRESTAT(R) in Pancreatic Neuroendocrine Tumor Model

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the...
15 oct. 2013 16h00 HE | Source: Mateon Therapeutics

OXiGENE to Present Preclinical Data Demonstrating Antitumor Activity of ZYBRESTAT(R) in Pancreatic Neuroendocrine Tumor Model

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
30 sept. 2013 12h59 HE | Source: Mateon Therapeutics

OXiGENE to Present at 12th Annual BIO Investor Forum Conference on October 8, 2013

SOUTH SAN FRANCISCO, Calif., Sept. 30, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
19 sept. 2013 12h40 HE | Source: Mateon Therapeutics

OXiGENE Announces $5.8 Million Private Placement

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that it...
03 sept. 2013 16h30 HE | Source: Mateon Therapeutics

OXiGENE Announces Presentation at the 15th Annual Rodman & Renshaw Global Investment Conference on September 9th

SOUTH SAN FRANCISCO, Calif., Sept. 3, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
06 août 2013 16h10 HE | Source: Mateon Therapeutics

OXiGENE Reports Second Quarter 2013 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 6, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial...
24 juil. 2013 16h00 HE | Source: Mateon Therapeutics

OXiGENE Announces Second Quarter 2013 Earnings Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., July 24, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report second...
18 juil. 2013 16h11 HE | Source: Mateon Therapeutics

OXiGENE Announces Granting of Orphan Drug Status in Europe for ZYBRESTAT in Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., July 18, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that the...
10 juin 2013 09h00 HE | Source: Mateon Therapeutics

OXIGENE Announces Publication of Final FACT Study Data in Journal Thyroid Suggest Survival Benefit of ZYBRESTAT(R) in Patients With Anaplastic Thyroid Cancer

SOUTH SAN FRANCISCO, Calif., June 10, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer, announced the...
06 mai 2013 16h00 HE | Source: Mateon Therapeutics

OXiGENE Reports First Quarter 2013 Financial Results

SOUTH SAN FRANCISCO, Calif., May 6, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial...

Page précédente